Key result
The presence of metabolic syndrome in nondiabetic hypertensive patients was associated with a significantly higher prevalence of left ventricular hypertrophy (57.7% vs 25.1%, OR 2.89) compared to those without the syndrome.
Odds Ratio: 2.89 (95% CI 1.68–4.98)
Absolute Event Rate: 57.7% vs 25.1%
p-value: p=<0.00001
Metabolic syndrome is linked to preclinical target organ damage, which may explain the high rates of cardiovascular morbidity and mortality observed in these patients.
No takes yet. Share an insight, caveat, or question.
May warrant enhanced LVH evaluation in nondiabetic hypertensives with metabolic syndrome; leaves open causal and therapeutic implications.
Mulè et al. (2006) conducted a review in Essential hypertension (n=353). Metabolic syndrome vs. Without metabolic syndrome was evaluated on Left ventricular hypertrophy (OR 2.89, 95% CI 1.68-4.98, p=<0.00001). The presence of metabolic syndrome in nondiabetic hypertensive patients was associated with a significantly higher prevalence of left ventricular hypertrophy (57.7% vs 25.1%, OR 2.89) compared to those without the syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: